CoChat
Sign Up
Cited by 102

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Role of Family History of Sudden Death in Risk Stratification and Prevention of Sudden Death With Implantable Defibrillators in Hypertrophic Cardiomyopathy

Bos, J. Martijn, Maron, Barry J., Ackerman, Michael J., Haas, Tammy S., Sorajja, Paul, Nishimura, Rick A., Gersh, Bernard J., Ommen, Steve R.·2010·The American Journal of Cardiology
DOI 10.1016/j.amjcard.2010.06.077
Open this paper in CoChat — free account

Abstract

The selection of patients with hypertrophic cardiomyopathy (HC) for the primary prevention of sudden death (SD) with implantable cardioverter-defibrillators (ICDs) has been determined by the assessment of 5 risk factors. We examined one of these markers, the family history of HC-related SD in first-degree relatives, for which few data are available. The rate of appropriate ICD interventions was assessed in 177 consecutive patients with HC (63% men, age 45 ± 14 years) who had undergone prophylactic implantation at 2 tertiary centers, according to the identification of ≥ 1 risk markers. During a follow-up period of 4.6 ± 3 years, 25 patients (14%) had experienced appropriate ICD interventions for ventricular tachycardia/fibrillation. The patients with a risk profile that included a family history of SD experienced interventions at a similar rate (3.7/100 person-years) as the patients without a family history of SD (3.1/100 person-years, p = 0.2). The rate and frequency of appropriate ICD interventions in 42 patients who had undergone implantation solely because of a family history of SD was 2.2/100 person-years (4/42, 10%), similar to that for patients with one risk factor other than SD family history (3.4%/100 person-years; 7/50, 14%; p = 0.2) and patients with multiple risk factors with (4.5/100 person-years; 9/49, 18%) and without (3.5/100 person-years; 5/36, 14%) a family history of SD (p = 0.8). In conclusion, a family history of SD is an important risk marker in patients…

Overview

Integrity signals

Registry

Crossref · 10.1016/j.amjcard.2010.06.077

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Family history of sudden death in first degree relatives before age 40-50 has been validated in one study showing a similar rate of ICD interventions for those implanted for only this risk factor compared with those with other risk factors, as well as in multivariable models of risk.

    “Family history of sudden death in first degree relatives before age 40-50, long considered a marker of risk, has been validated in one study showing a similar rate of ICD interventions for those implanted for only this risk factor compared with those with other risk factors, 102 as well as in multivariable models of risk.”

    From Current management of hypertrophic cardiomyopathy (2025) · cites this paper as [102]

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 28

  1. Maron, 2009, Sudden deaths in young competitive athletes: analysis of 1866 deaths in the United States, 1980–2006, Circulation, 119, 1085, 10.1161/CIRCULATIONAHA.108.804617 · DOI
  2. Maron, 2003, J Am Coll Cardiol, 42, 1687, 10.1016/S0735-1097(03)00941-0 · DOI
  3. Maron, 2000, Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population, Circulation, 102, 858, 10.1161/01.CIR.102.8.858 · DOI · Paper page
  4. Spirito, 1997, The management of hypertrophic cardiomyopathy, N Engl J Med, 336, 775, 10.1056/NEJM199703133361107 · DOI
  5. Maron, 2000, Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy, N Engl J Med, 342, 365, 10.1056/NEJM200002103420601 · DOI · Paper page
  6. Maron, 2007, Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy, JAMA, 298, 405, 10.1001/jama.298.4.405 · DOI
  7. Elliott, 2000, Sudden death in hypertrophic cardiomyopathy: identification of high risk patients, J Am Coll Cardiol, 36, 2212, 10.1016/S0735-1097(00)01003-2 · DOI
  8. Maron, 2006, Circulation, 113, 1807, 10.1161/CIRCULATIONAHA.106.174287 · DOI
  9. McKenna, 2002, Hypertrophic cardiomyopathy: management, risk stratification, and prevention of sudden death, Heart, 87, 169, 10.1136/heart.87.2.169 · DOI
  10. Elliott, 2001, Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy, Lancet, 357, 420, 10.1016/S0140-6736(00)04005-8 · DOI
  11. Maron, 2003, Contemporary considerations for risk stratification, sudden death and prevention in hypertrophic cardiomyopathy, Heart, 89, 977, 10.1136/heart.89.9.977 · DOI
  12. Maron, 2003, Primary prevention of sudden death as a novel treatment strategy in hypertrophic cardiomyopathy, Circulation, 107, 2872, 10.1161/01.CIR.0000072343.81530.75 · DOI
  13. Olivotto, 1999, Prognostic value of systemic blood pressure response during exercise in a community-based patient population with hypertrophic cardiomyopathy, J Am Coll Cardiol, 33, 2044, 10.1016/S0735-1097(99)00094-7 · DOI
  14. Spirito, 2000, Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy, N Engl J Med, 342, 1778, 10.1056/NEJM200006153422403 · DOI
  15. Hauser, 2005, Lessons from the failure and recall of an implantable cardioverter-defibrillator, Circulation, 112, 2040, 10.1161/CIRCULATIONAHA.105.580381 · DOI
  16. Jayatilleke, 2004, Long-term follow-up of implantable cardioverter defibrillator therapy for hypertrophic cardiomyopathy, Am J Cardiol, 93, 1192, 10.1016/j.amjcard.2004.01.057 · DOI
  17. Maron, 2008, Implantable defibrillators and prevention of sudden death in hypertrophic cardiomyopathy, J Cardiovasc Electrophysiol, 19, 1118, 10.1111/j.1540-8167.2008.01147.x · DOI
  18. Woo, 2007, Determinants of implantable defibrillator discharges in high-risk patients with hypertrophic cardiomyopathy, Heart, 93, 1044, 10.1136/hrt.2006.090290 · DOI
  19. Nishimura, 2007, Hypertrophic cardiomyopathy, sudden death, and implantable cardiac defibrillators: how low the bar?, JAMA, 298, 452, 10.1001/jama.298.4.452 · DOI
  20. Cecchi, 1995, Hypertrophic cardiomyopathy in Tuscany: clinical course and outcome in an unselected regional population, J Am Coll Cardiol, 26, 1529, 10.1016/0735-1097(95)00353-3 · DOI
  21. Maron, 1999, Clinical course of hypertrophic cardiomyopathy in a regional United States cohort, JAMA, 281, 650, 10.1001/jama.281.7.650 · DOI
  22. Ellenbogen, 2006, Are implantable cardioverter defibrillator shocks a surrogate for sudden cardiac death in patients with nonischemic cardiomyopathy?, Circulation, 113, 776, 10.1161/CIRCULATIONAHA.105.561571 · DOI
  23. Cuoco, 2008, Implantable cardioverter-defibrillator therapy for primary prevention of sudden death after alcohol septal ablation of hypertrophic cardiomyopathy, J Am Coll Cardiol, 52, 1718, 10.1016/j.jacc.2008.07.061 · DOI
  24. Elliott, 2006, Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy, Eur Heart J, 27, 1933, 10.1093/eurheartj/ehl041 · DOI
  25. Maron, 2003, Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy, N Engl J Med, 348, 295, 10.1056/NEJMoa021332 · DOI · Paper page
  26. McLeod, 2007, Surgical septal myectomy decreases the risk for appropriate implantable cardioverter defibrillator discharge in obstructive hypertrophic cardiomyopathy, Eur Heart J, 28, 2583, 10.1093/eurheartj/ehm117 · DOI
  27. Maron, 2008, Prevalence, clinical significance and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy, Circulation, 118, 1541, 10.1161/CIRCULATIONAHA.108.781401 · DOI
  28. Lin, 2009, Device complications and inappropriate implantable cardioverter defibrillator shocks in patients with hypertrophic cardiomyopathy, Heart, 95, 709, 10.1136/hrt.2008.150656 · DOI

Cited by

Sorted by citations

Metadata

Authors
Bos, J. M., Maron, B. J., Ackerman, M. J., Haas, T. S., Sorajja, P., Nishimura, R. A., Gersh, B. J., & Ommen, S. R.
Venue
The American Journal of Cardiology
Publisher
Elsevier BV
Published
2010-11
Volume
106
Issue
10
Pages
1481-1486
ISSN
0002-9149
DOI
10.1016/j.amjcard.2010.06.077
Cited by
102
References
4
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review